NCT04802759 2026-04-13
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer
Hoffmann-La Roche
Phase 1/2 Recruiting
Clinical Trials
15 trialsNCT06625775 2026-04-13
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Phase 1 Recruiting
NCT06663787 2026-04-13
HER2 CR
Nagoya City University
Active not recruiting
NCT07007559 2026-04-13
ASPEN-09-03
ALX Oncology Inc.
Phase 2 Recruiting
NCT05143970 2026-03-20
CHANCES
Institut Paoli-Calmettes
Phase 1 Recruiting
NCT01613482 2026-03-16
TSARINE
Centre Oscar Lambret
Phase 3 Terminated
NCT05081609 2026-02-24
IL Believe
Ascendis Pharma A/S
Phase 1/2 Active not recruiting
NCT07193394 2026-02-23
H3RAKLES
Institut Curie
Phase 2 Recruiting
NCT04784715 2026-02-20
Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)
AstraZeneca
Phase 3 Active not recruiting
NCT00781612 2025-12-24
A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies
Genentech, Inc.
Phase 2 Active not recruiting
NCT01771458 2025-11-24
SHIVA
Institut Curie
Phase 2 Completed
NCT03013218 2025-08-01
A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01)
ALX Oncology Inc.
Phase 1 Completed
NCT00393783 2025-06-05
Xenogeneic HER2/Neu DNA Immunization for Patients With Metastatic and High Risk Breast Cancer: A Phase I Study to Assess Safety and Immunogenicity
Memorial Sloan Kettering Cancer Center
Phase 1 Active not recruiting
NCT00317720 2025-04-30
Trastuzumab and RAD001 in Patients With Human Epidermal Growth Receptor 2 (HER-2) Overexpressing Breast Cancer
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT05525858 2025-04-27
KOSMOSII
Seoul National University Bundang Hospital
Recruiting